Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Drug development

Ketamine metabolite relieves depression with fewer side effects

Study findings could inform the development of more effective and safe treatments for depression.

Crossed polars of ketamine, crystallised from an aqueous solution

Source: M. I. Walker / Science Photo Library

Researchers are trying to develop drugs for depression based on ketamine (crystals pictured) 

Ketamine has shown promise as a rapid-onset treatment for severe depression, but its mechanism of action is unclear. 

Reporting in Nature (online, 4 May 2016)[1], researchers studied the effect of ketamine metabolites in mice. They found that blocking formation of one particular metabolite – (2S,6S;2R,6R) hydroxynorketamine – prevented the antidepressant effect of ketamine. 

The team then showed that the metabolite can induce antidepressant effects similar to ketamine but without the related side effects. This action was not via inhibition of N-methyl-d-aspartate receptors (NMDAR), as ketamine has previously been thought to work, but via α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs), another type of glutamate receptor in the brain. 

The researchers say that the findings are relevant to the development of more effective and safe treatments for depression.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201158

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Crossed polars of ketamine, crystallised from an aqueous solution

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.